238 related articles for article (PubMed ID: 34880242)
1. Structural basis for transthyretin amyloid formation in vitreous body of the eye.
Iakovleva I; Hall M; Oelker M; Sandblad L; Anan I; Sauer-Eriksson AE
Nat Commun; 2021 Dec; 12(1):7141. PubMed ID: 34880242
[TBL] [Abstract][Full Text] [Related]
2. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis.
Schmidt M; Wiese S; Adak V; Engler J; Agarwal S; Fritz G; Westermark P; Zacharias M; Fändrich M
Nat Commun; 2019 Nov; 10(1):5008. PubMed ID: 31676763
[TBL] [Abstract][Full Text] [Related]
3. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.
Saelices L; Chung K; Lee JH; Cohn W; Whitelegge JP; Benson MD; Eisenberg DS
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6741-E6750. PubMed ID: 29954863
[TBL] [Abstract][Full Text] [Related]
4. Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis.
Steinebrei M; Baur J; Pradhan A; Kupfer N; Wiese S; Hegenbart U; Schönland SO; Schmidt M; Fändrich M
Nat Commun; 2023 Nov; 14(1):7623. PubMed ID: 37993462
[TBL] [Abstract][Full Text] [Related]
5. Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis.
Steinebrei M; Gottwald J; Baur J; Röcken C; Hegenbart U; Schönland S; Schmidt M
Nat Commun; 2022 Oct; 13(1):6398. PubMed ID: 36302762
[TBL] [Abstract][Full Text] [Related]
6. A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.
Ueda M; Okada M; Mizuguchi M; Kluve-Beckerman B; Kanenawa K; Isoguchi A; Misumi Y; Tasaki M; Ueda A; Kanai A; Sasaki R; Masuda T; Inoue Y; Nomura T; Shinriki S; Shuto T; Kai H; Yamashita T; Matsui H; Benson MD; Ando Y
J Biol Chem; 2019 Jul; 294(29):11259-11275. PubMed ID: 31167790
[TBL] [Abstract][Full Text] [Related]
7. Structural polymorphism of amyloid fibrils in ATTR amyloidosis revealed by cryo-electron microscopy.
Nguyen BA; Singh V; Afrin S; Yakubovska A; Wang L; Ahmed Y; Pedretti R; Fernandez-Ramirez MDC; Singh P; Pękała M; Cabrera Hernandez LO; Kumar S; Lemoff A; Gonzalez-Prieto R; Sawaya MR; Eisenberg DS; Benson MD; Saelices L
Nat Commun; 2024 Jan; 15(1):581. PubMed ID: 38233397
[TBL] [Abstract][Full Text] [Related]
8. Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils.
Cardoso I; Goldsbury CS; Müller SA; Olivieri V; Wirtz S; Damas AM; Aebi U; Saraiva MJ
J Mol Biol; 2002 Apr; 317(5):683-95. PubMed ID: 11955017
[TBL] [Abstract][Full Text] [Related]
9. Modeling transthyretin (TTR) amyloid diseases, from monomer to amyloid fibrils.
Criddle RS; Hansen LD; Woodfield BF; Tolley HD
PLoS One; 2024; 19(6):e0304891. PubMed ID: 38843135
[TBL] [Abstract][Full Text] [Related]
10. Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition.
Arvidsson S; Pilebro B; Westermark P; Lindqvist P; Suhr OB
PLoS One; 2015; 10(11):e0143456. PubMed ID: 26600306
[TBL] [Abstract][Full Text] [Related]
11. Tafamidis in hereditary ATTR amyloidosis - our experience on monitoring the ocular manifestations.
Casal I; Monteiro S; Beirão JM
Amyloid; 2016 Dec; 23(4):262-263. PubMed ID: 27748624
[No Abstract] [Full Text] [Related]
12. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition.
Suhr OB; Lundgren E; Westermark P
J Intern Med; 2017 Apr; 281(4):337-347. PubMed ID: 28093848
[TBL] [Abstract][Full Text] [Related]
13. A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis).
Gonzalez-Duarte A; Ulloa-Aguirre A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884963
[TBL] [Abstract][Full Text] [Related]
14. Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis.
Slamova I; Adib R; Ellmerich S; Golos MR; Gilbertson JA; Botcher N; Canetti D; Taylor GW; Rendell N; Tennent GA; Verona G; Porcari R; Mangione PP; Gillmore JD; Pepys MB; Bellotti V; Hawkins PN; Al-Shawi R; Simons JP
Nat Commun; 2021 Dec; 12(1):7112. PubMed ID: 34876572
[TBL] [Abstract][Full Text] [Related]
15. Amyloid fibril composition within hereditary Val30Met (p. Val50Met) transthyretin amyloidosis families.
Suhr OB; Wixner J; Anan I; Lundgren HE; Wijayatunga P; Westermark P; Ihse E
PLoS One; 2019; 14(2):e0211983. PubMed ID: 30811423
[TBL] [Abstract][Full Text] [Related]
16. Uncovering the Mechanism of Aggregation of Human Transthyretin.
Saelices L; Johnson LM; Liang WY; Sawaya MR; Cascio D; Ruchala P; Whitelegge J; Jiang L; Riek R; Eisenberg DS
J Biol Chem; 2015 Nov; 290(48):28932-43. PubMed ID: 26459562
[TBL] [Abstract][Full Text] [Related]
17. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
Lashuel HA; Wurth C; Woo L; Kelly JW
Biochemistry; 1999 Oct; 38(41):13560-73. PubMed ID: 10521263
[TBL] [Abstract][Full Text] [Related]
18. Deposition of transthyretin amyloid is not accelerated by the same amyloid in vivo.
Wei L; Kawano H; Fu X; Cui D; Ito S; Yamamura K; Ishihara T; Tokuda T; Higuchi K; Maeda S
Amyloid; 2004 Jun; 11(2):113-20. PubMed ID: 15478467
[TBL] [Abstract][Full Text] [Related]
19. Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation.
Esperante SA; Varejāo N; Pinheiro F; Sant'Anna R; Luque-Ortega JR; Alfonso C; Sora V; Papaleo E; Rivas G; Reverter D; Ventura S
J Biol Chem; 2021 Sep; 297(3):101039. PubMed ID: 34343569
[TBL] [Abstract][Full Text] [Related]
20. Disulfide-bond formation in the transthyretin mutant Y114C prevents amyloid fibril formation in vivo and in vitro.
Eneqvist T; Olofsson A; Ando Y; Miyakawa T; Katsuragi S; Jass J; Lundgren E; Sauer-Eriksson AE
Biochemistry; 2002 Nov; 41(44):13143-51. PubMed ID: 12403615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]